Generic Name and Formulations:
Methylphenidate 10mg, 15mg, 20mg, 30mg; delivered over 9hrs; transdermal patches.
Indications for DAYTRANA:
Attention deficit hyperactivity disorder.
<6yrs: not established. 6–17yrs: Initially apply one 10mg patch to hip 2hrs before desired effect, remove 9hrs after application; may remove earlier if shorter duration of effect or late day side effects appear. May titrate dose at 1-week intervals. Reevaluate periodically. Rotate application sites.
Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family. During or within 14 days of MAOIs.
History of drug dependence or alcoholism; monitor for abnormal behavior. Discontinue if contact sensitization is suspected; may develop systemic sensitization with other MPH formulations (see full labeling). Avoid exposing patch to direct external heat sources. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. History of vitiligo. Monitor for signs of skin depigmentation; discontinue if chemical leukoderma develops. Monitor growth, BP, HR, CBCs, differential, platelet counts. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Hypertensive crisis with MAOIs. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), tricyclics (eg, imipramine, clomipramine, desipramine), SSRIs. May decrease effectiveness of antihypertensive agents. Caution with pressor agents. Risk of serotonin syndrome with serotonergic drugs.
Application site reactions (eg, erythema), decreased appetite, insomnia, nausea, vomiting, weight loss, tics, affect lability, anorexia, dizziness, abdominal pain, headache, irritability; priapism, hypertension, tachycardia, visual disturbances.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Rapid Cycling in Bipolar Disorder: Overview and Expert Perspectives
- First-Episode Drug-Naive Patients With Schizophrenia More Likely to Attempt Suicide
- Posttraumatic Stress Disorder Associated With Reduced Brain Volume
- Early Childhood Out-of-Home Placement Associated With Adverse Outcomes in Adulthood
- ADHD Medications Compared for Efficacy, Tolerability in Children and Adults
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation
- Symptoms of Anxiety, Depression Differ Depending on Gender, Race, Ethnicity
- Examining Whether Adjunctive Glutamatergic Medication Further Eases OCD Symptoms
- FDA Permits Marketing of Brain Stimulation Device for OCD
- Antipsychotics Adversely Affect Adiposity and Insulin Sensitivity in Youths
- Know Before You Go: Practicing Medicine Abroad